Biopsies from patients with high-risk (HR) non-muscle-invasive urothelial carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. This study evaluated the use of next-generation sequencing (NGS) analysis of urine cytology material from patients with HR NMIUC in an attempt to identify genetic alterations that might correlate with clinical features and responses to bacille Calmette-Gu erin (BCG) treatment. METHODS: Forty-one cytology slides from patients with HR NMIUC treated with intravesical BCG were selected for this study. Histological confirmation was available for all cases. The specimens were subjected to NGS analysis with a customized targeted exome capture assay composed of 341 genes. RESULTS: In this cohort, genomic alterations were successfully identified in all cytology samples. Mutations were detected down to a 2% allele frequency and chromosomal rearrangements including copy number alterations and 
INTRODUCTION
Urothelial carcinoma of the bladder (UCB) is the fifth most common cancer in the United States, with an estimated 77,000 new cases diagnosed in the United States in 2016. [1] [2] [3] [4] Among the newly diagnosed UCB patients, approximately 30% will present with high-risk (HR) non-muscle-invasive urothelial carcinoma (NMIUC), a
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disease confined to the epithelium or subepithelial connective tissue of the bladder (stage Ta, Tis, or T1). [5] [6] [7] Approximately 20% of these HR NMIUC cases will eventually progress to muscle-invasive disease (stage T2, T3, or T4) leading to a worse prognosis. 8, 9 Disease management of HR NMIUC relies on the microscopic pathological examination of tissue or cells obtained from cystoscopic examinations. Although the pathological evaluation of this material remains the standard of care, it is limited in its scope for predicting individual recurrence, progression risk, and drug responsiveness. 10, 11 In recent years, the clinical management of cancer has greatly benefitted from the rapid progression in the area of genomics and particularly next-generation sequencing (NGS). [12] [13] [14] [15] Molecular diagnostics using NGS allows higher analytical sensitivity and the simultaneous analysis of numerous target genes and pathways for better tumor management and personalized drug therapies. 10, [15] [16] [17] However, even with the ability to use smaller amounts of DNA and target technically challenging lesions, genomic profiling has been primarily restricted to tissue samples, including formalin-fixed, paraffin-embedded (FFPE) cell blocks. These samples are obtained from invasive surgical procedures, which can increase the risk of patient complications and the cost of clinical management. [18] [19] [20] Other disadvantages in the use of FFPE material include the fact that DNA from FFPE is often moderately degraded with insufficient tumor cellularity and a lack of subclonal tumor heterogeneity. [21] [22] [23] [24] [25] These factors limit the ability to assess the association of different biomarkers with disease progression and drug responses in specimens with limited tissue available for analysis. Because of these factors, other sample types such as effusion cytology and fine-needle aspiration specimens have been recognized as potential alternatives to FFPE for NGS analysis. 18, 20 In this context, urine cytology specimens represent a potential source for the genomic analysis of HR NMIUC, especially in patients with flat urothelial carcinoma in situ (CIS). Biopsies from patients with flat urothelial CIS frequently contain scant diagnostic material or denuded mucosa only, and this precludes further extensive genomic analysis. On the other hand, urine cytology specimens obtained from patients with HR NMIUC are frequently cellular and contain enough DNA for genomic analysis. Therefore, urine cytology specimens could represent a platform for the identification of biomarkers associated with clinical features, particularly biomarkers associated with a response to bacille Calmette-Gu erin (BCG) treatment in patients with HR NMIUC. Substratification of patients with HR NMIUC into responders and nonresponders to BCG treatment represents a major need currently because it is not possible to predict who will respond favorably to BCG and who might benefit from early aggressive treatment, such as cystectomy, to achieve a cure. 26 More recently, the European Organization for Research and Treatment of Cancer reiterated the need for molecular markers to better optimize patient selection and treatment strategies for patients with HR NMIUC treated with BCG. 27 In this study, we evaluated the use of NGS analysis of urine cytology materials from patients with HR NMIUC. We analyzed the suitability of cytology specimens as replacements for FFPE material for genomic analysis and attempted to identify mutations or copy-number alterations that might correlate with clinical features and responses to BCG treatment.
MATERIALS AND METHODS

Specimens
Fifty-two specimens from 41 patients with histologically proven HR NMIUC treated with intravesical BCG instillation were selected for this study. The study was reviewed and approved by the Institution Review Board before initiation of the study. These samples included 41 ThinPreps or cytospins from urine cytology slides, 5 FFPE sections from matching cystectomy specimens, and 6 FFPE Next-Generation Sequencing of Urine/Scott et al
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June 2017 germline (nontumor) tissue samples from the same cohort of patients for use as a genetic reference. The cytology slides had been CytoLyt-fixed, Papanicolaou-stained, and archived for at least 10 years (range, 10-12 years), and they were obtained from both cystoscopic and voided urine specimens. All cytology slides were morphologically confirmed by a board-certified cytopathologist for the presence and percentage of tumor cells. All specimens satisfied the criteria of highgrade urothelial carcinoma as defined in the Paris System for Reporting Urinary Cytology, including a minimum of 5 to 10 severely abnormal urothelial cells and a nuclearcytoplasmic ratio of 0.7 or greater, with cells showing moderate to severe hypochromasia, coarse chromatin, and markedly irregular nuclear membranes. 28 Only cellular specimens containing at least 1000 neoplastic cells with tumor cells representing more than 50% of the cell population in the cytology preparation were included in this study (Fig. 1) . Thirty percent of the cases that matched our clinical and morphological criteria satisfied the cellularity criteria.
Sample Preparation
Tumor DNA from cytology slides (1 slide per sample) was extracted first by the dispersion of 50 lL of Qiagen ATL buffer onto each slide and then by the scraping of the cells into 1.5-mL Eppendorf tubes with a sterile surgical blade. This was repeated twice for each slide, and the blade was rinsed with 30 lL of the buffer; this resulted in a final ATL buffer volume of 180 lL. Then, 20 to 40 lL of proteinase K was added, and the mixture was then vortexed and incubated at 568C. Lysates were then purified according to the Qiagen DNeasy protocol with an elution volume of 100 lL with the Qiagen QIAamp DNA tissue kit (Qiagen, Inc, Valencia, Calif) according to the manufacturer's protocol released in April 2010. DNA from FFPE tissue sections was extracted manually. Only tumor tissue sections that were represented by at least 50% neoplastic cells were selected. The QIAamp DNA FFPE tissue kit (Qiagen, Inc) was used according to the manufacturer's instructions. All extracted cytospin and FFPE DNA was quantified with the dsQubit DNA assay (Life Technologies Corporation, Grand Island, NY).
Targeted NGS and Sequence Analysis
The extracted tumor samples and the germline DNA samples from normal tissue were both prepared with the Memorial Sloan Kettering Integrated Molecular Profiling of Actionable Cancer Targets (MSK-IMPACT) assay. 29, 30 MSK-IMPACT is a targeted exon capture assay that uses target-specific probes to profile all protein-coding exons and select introns of 341 cancer-associated genes (Supporting Table 1 [see online supporting information]). It is followed by massive parallel sequencing performed on an Illumina HiSeq 2500 (Illumina, Inc, San Diego, Calif; 2 3 100 base paired reads). The genomic data obtained from the MSK-IMPACT assay include somatic mutations, structural variants, and copy-number alterations from the 341-gene panel. For the purpose of this analysis, we manually reviewed all nonsynonymous mutations, indels, and structural aberrations with the Integrative Genomics Viewer. 16, 19 Copy-number variants were declared to be amplified if the fold change was 2 and deleted if the fold change was -2. Further details on the experimental methodology, algorithms used for mutation calling, and run statistics for MSK-IMPACT have been described previously.
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Data Availability
All associated clinical data were obtained from prospectively maintained medical records. Genomic and clinical data are publicly available through the Memorial Sloan Kettering Cancer Center cBioPortal for Cancer Genomics.
21,31
Statistical Analysis
The patients were subdivided into 2 categories: responders (patients with no evidence of disease after 1 cycle of BCG for at least 2 years) and refractory patients (patients with no response to treatment). The criteria for inclusion in each category followed the European Organization for Research and Treatment of Cancer guidelines. We used the Wilcoxon rank-sum test and Fisher's exact test to analyze the 2 patient groups' distributions of demographic characteristics (Table 1) . We performed univariate analyses to evaluate alteration frequencies and pathways within our cohort and compared our cohort against 125 patients with both copy-number and mutation data from The Cancer Genome Atlas (TCGA) for UCB. 32 Statistical analyses were also performed to identify differences associated with a smoking history and histological findings (particularly architecture and the presence or absence of invasion). Statistical analyses were conducted with SAS 9.2 (SAS Institute, Cary, NC) and R 3.2.0 (R Core Development Team, Vienna, Austria). All P values < .05 were considered statistically significant. Because this study was hypothesis-generating, no adjustment for multiple comparisons was performed.
RESULTS
The demographic and clinical characteristics of the 41 UCB patients included in this study are summarized in Table 1 . Among the 41 patients, there were 29 patients (71%) with disease refractory to BCG treatment and 12 patients (29%) who responded to 1 cycle of BCG intravesical therapy. The patients who responded to BCG either had no recurrence or were disease-free for more than 2 years. Clinical follow-up was available for all patients. Overall, our patient population had a median age of 66 years (interquartile range, 49-83 years) and was predominantly male (61%) with a smoking history (68%).
The average amount of DNA extracted from 41 cytospin slides was 263 ng (range, 17-2080 ng). Targeted sequencing with MSK-IMPACT was performed for 41 cytospin tumor samples, 5 matched FFPE tumor samples from subsequent cystectomy specimens, and 6 matched germline samples from 41 UCB patients. The mean sequencing coverage for all tumor and normal samples across 4980 exons and introns in the 341-gene IMPACT panel was 3903, with only 1% of exons covered below 1003 (Fig. 2) . A total of 497 nonsynonymous mutations and 137 gene-level copy-number alterations were identified for all cytospin samples in our cohort. The mean number of somatic alterations (mutations and copy number) per patient was 15.5 (range, 2-44). Altogether, 231 of 341 genes were altered in at least 1 patient. The most frequently altered genes across our patient cohort are displayed in Figure 3A . Telomerase reverse transcriptase (TERT) was the single most frequently altered gene, with mutations observed in 61% of the cases (25 of 41). Of these 25 alterations, 24 were at 1 of 2 well-characterized mutational hotspots in the promoter region, and 1 represented an amplification (Fig. 3B) . The majority of the remaining commonly altered genes were chromatin remodeling genes: lysine demethylase 6A (KDM6A; 34%), AT-rich interaction domain 1A (ARID1A; 27%), lysine methyltransferase 2D (KMT2D; 24%), fibroblast growth factor receptor 3 (FGFR3; 20%), CREB binding protein (CREBBP; 17%), and E1A binding protein P300 (EP300; 17%). In addition to mutations and copy-number alterations, MSK-IMPACT was able to successfully detect chromosomal rearrangements in urine cytology specimens, including an intrachromosomal duplication producing the recurrent FGFR3-transforming acidic coiled-coil containing protein 3 (TACC3) gene fusion on chromosome 4 (Fig. 3C) .
To confirm that the alterations we detected in urine were representative of bladder cancer, we compared our results to the ones obtained in TCGA for UCB (Fig. 4) . 32 Our cohort and TCGA's urothelial carcinoma cohort were highly concordant. Of the 20 genes mutated in at least 10% of patients in both cohorts, only 4 genes exhibited statistically significant differences in alteration prevalence between the 2 studies according to a univariate analysis. TERT (61% vs 10%; P < .001) and Erb-B2 receptor tyrosine kinase 2 (ERBB2; 29% vs 12%; P 5 .01) were altered more frequently in our cohort, whereas cyclin dependent kinase inhibitor 2A (CDKN2A; 15% vs 41%; P 5 .02) and CDKN2B (15% vs 37%; P 5 .02) were altered more frequently in TCGA (Fig. 4) . The underrepresentation of deletions of CDKN2A and CDKN2B, adjacent genes on chromosome 9, could indicate a reduced sensitivity of our targeted sequencing assay for identifying deletions in particular, which was due in part to conservative thresholds for calling copy-number alterations. However, the enrichment of TERT mutations is completely explained by the inclusion of the TERT promoter in our sequencing panel and its omission from the whole-exome sequencing assay used by TCGA. FGFR3-TACC3 gene fusions were observed in both TCGA and our cohort at a 2% frequency.
A correlation of genetic alterations with a response to BCG treatment demonstrated differences between the 2 patient categories (response and refractory). Genetic alterations in RNA Binding Motif Protein 10 (RMB10) and EPH receptor A3 (EPHA3) were statistically more frequent in the responder category in comparison with patients refractory to BCG (42% vs 10% [P 5 .04] and 25% vs 0% [P 5 .02], respectively). No genes were detected to be statistically significantly more common in patients with refractory disease; however, genes such as ARID1A, EP300, and CDKN1A were observed more often for these patients versus responders (35% vs 8%, 21% vs 8%, and 17% vs 8%, respectively).
We found that alterations in the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, which included genes ARID1A, ARID1B, and SWI/SNFrelated, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), were more common in flat tumor architecture versus tumors with a papillary architecture (59% vs 21%; P 5 .03).
Other genes associated with a flat architecture included tumor protein 53 (TP53; 55% vs 16%; P 5 .02), succinate dehydrogenase complex subunit C (SDHC; 32% vs 5%; P 5 .05), BRCA1 interacting protein C-terminal helicase 1 (BRIP1; 23% vs 0%; P 5 .05), and neurofibromin 1 (NF1; 23% vs 0%; P 5 .05). Conversely, FGFR3 was altered more often in tumors with a papillary architecture (5% vs 37%; P 5 .02). An analysis of different tumor stages (pTa, pTis, pT1, and T1) demonstrated the presence of alterations in forkhead box L2 (FOXL2; P 5 .03) and protein tyrosine phosphatase receptor type S (PTPRS; P 5 .03) only in patients with a pT1 tumor stage.
We also investigated alterations associated with a smoking history and found that Mouse double minute 2 homolog (MDM2) amplifications (0% vs 32%; P 5 .04) were exclusively found in patients who had a history of smoking. Meanwhile, ATM serine/threonine kinase (ATM) and SMARCA4 were more commonly altered in patients with no history of smoking (39% vs 4% [P 5
.01] and 23% vs 0% [P 5 .03], respectively).
A comparison of the results for urine cytology specimens and matching FFPE tumor samples from 5 different patients is summarized in Figure 5 . Every mutation identified in the FFPE samples was independently called in the corresponding urine cytospin with a comparable allele frequency. However, not every mutation called in the urine cytospins was detectable in the corresponding FFPE sample. Only 2 of the 5 patients exhibited 100% concordance between urine and FFPE samples. In 3 of the 5 patients, at least 3 mutations present in urine were completely absent in FFPE tissue; they included known oncogenic mutations in PIK3CA, TERT, and SMAD3 genes. Altogether, we detected 31% more mutations in urine than FFPE tissue, and this indicates that urine may more effectively capture the full genetic heterogeneity of a patient's cancer.
DISCUSSION
The approach to the identification of UCB biomarkers in this study is unique because it uses urine cytology specimens for NGS analysis instead of traditional FFPE or frozen specimens. Urine cytology specimens have several advantages over FFPE material. They are easier to obtain with minimal risk and discomfort to the patient in comparison with other conventional tumor-collection methods, and they are inexpensive. 18, 20 Also, they are more sensitive for detecting flat CIS than cystoscopic bladder biopsies. 22, 23 Also, urine specimens can theoretically capture the full heterogeneity of a patient's disease more effectively than a single localized tissue biopsy. An important finding of this study is that urine specimens not only are suitable for detecting genomic alterations with high accuracy and sensitivity but also seem to be superior to FFPE specimens. Only approximately 2% of the urine samples in our cohort had an average coverage below 2003, whereas 20% of the FFPE samples did; this could indicate that FFPE degradation had an effect on the DNA yields and on sequencing coverage. Furthermore, our results demonstrated that urine cytology specimens detected an equal number of genomic alterations or more in comparison with FFPE specimens for all 5 patients for whom tumor tissue was available from cystectomy specimens. No genomic alteration seen in the FFPE specimens was missed in the urine cytology specimen analysis, and overall, 31% more mutations were seen in the cytology specimens. These results were obtained even though the specimens used had been in storage for more than 10 years for regulatory reasons that required the cytology slides to remain intact for 10 years. These findings, in conjunction with the better coverage seen in the NGS analysis, confirm that urine cytology specimens can effectively replace FFPE specimens in the genomic analysis of HR NMIUC. This fulfills a major need in the NGS analysis of urothelial CIS because no concurrent biopsy containing urothelial CIS contained sufficient material for NGS analysis. We compared our cohort with the gene prevalence observed by TCGA. 33 Similarly to TCGA's findings, we found that the majority of the most commonly altered genes were ones associated with chromatin remodeling, such as KDM6A, ARID1A, KMT2D, FGFR3, CREBBP, and EP300. Another similarity was the detection of FGFR3-TACC3 gene fusions in both TCGA's cohort and our cohort. Even though we found mostly similarities, we did observe some statistically significant differences between TCGA's cohort and our cohort. The largest difference between our study and TCGA was that TERT mutations were more frequently found in our cohort because of the inclusion of the TERT promoter region in MSK-IMPACT, whereas the promoter was absent in whole-exome data from TCGA. The incidence of mutations in the TERT promoter region in our cohort was very similar to a prior report of 74% in noninvasive urothelial neoplasms. 34 The lower frequencies of alterations in CDKN2A and CDKN2B observed in our cohort may be explained by a differential sensitivity for detecting deletions by MSK-IMPACT and array-based methods used by TCGA. We cannot explain why ERBB2 alterations were detected more often in our cytological samples, although it is notable that some of these mutations occur in the furinlike cysteine-rich region and the protein tyrosine kinase domain, which are commonly mutated codons in ERBB2 in UCB. Therefore, almost all variations in gene prevalence can be attributed to differences in the gene panels used or differences in pipeline calling criteria. One of the objectives of this study was to search for potential biomarkers that could predict a response to BCG in HR NMIUC. It is currently challenging to distinguish HR NMIUC patients who will benefit from BCG treatment and those who will benefit from early cystectomy. Cystectomy leads to excellent disease-free survival rates, but it represents overtreatment in more than 50% of cases because not all patients will progress to muscle-invasive disease. The current European Urological Association guidelines suggest treating HR NMIUC with BCG and proceeding to cystectomy in case of recurrence or progression, although upfront cystectomy remains an option. 7, 35 The problem with this approach is that patients who fail to achieve complete remission with BCG treatment have significantly lower survival rates than patients who are treated with upfront cystectomy. 36 In our study, 2 genes (RBM10 and EPHA3) were shown to be associated with a response to BCG in a univariate analysis. Unsurprisingly, RBM10 alterations have been previously associated with less aggressive urothelial carcinomas in comparison with higher grade or invasive UCBs. 37 Our analysis showed that the presence of RBM10 alterations was 6 times more likely in patients who responded to BCG treatment (odds ratio, 6). The other gene (EPHA3) associated with a response to BCG (P 5 .02) is one of the Eph receptor tyrosine kinases, which is an important family of signal transduction molecules that control many cellular processes, including cell adhesion and movement, cell shape, and cell growth. EPHA3 alterations are found in 5% to 10% of lung adenocarcinomas, 33 and the rate was 3% in the TCGA of UCB.
However, EPHA3's association with other clinical features in UCB has not been previously reported.
Although no alterations were found to be statistically significantly associated with refractoriness to BCG treatment, alterations in ARID1A, EP300, and CDKN1A tended to be more altered in patients who did not respond to BCG treatment. ARID1A is a member of the SWI/SNF chromatin remodeling complex. The incidence of ARID1A is variable in UCB and has varied from 25% to 30% in samples evaluated by other investigators, 32, 38, 39 except in the series reported by Gui et al, 40 who reported a lower incidence of 13%. The low number of ARID1A alterations in patients who responded to BCG (n 5 1 [8%]) in comparison with the 35% incidence in refractory patients suggests that ARID1A might be associated with a worse prognosis; however, statistical significance was not achieved. This finding would agree with the findings by Balbas-Martinez et al, 41 who described an association of ARID1A mutations with a higher stage and grade in urothelial bladder tumors, which led to a worse prognosis. Another gene in which alterations are more frequently seen for patients refractory to BCG is EP300, which is a histone acetyltransferase gene that has been previously reported to be altered in 13% of patients with bladder cancer. 40 The unaltered EP300 gene is believed to have a tumorsuppressor gene role in bladder cancer; thus, a mutation would silence its role as a tumor-suppressor gene.
CDKN1A is a regulator of progression in the G 1 and S phases of the cell cycle 42 and is controlled by p53 in response to a variety of stress stimuli. Data reported by Cazier et al 43 strongly suggest that a loss of CDKN1A function promotes the growth of bladder carcinomas and may augment defects caused by inactivation of p53.
The correlation of the genomic results with histological features supports previous findings seen in papillary lesions; our results demonstrate a strong association of FGFR3 mutations with a papillary architecture (P 5 .02). These findings are in line with prior studies using tissue sections that showed an association of FGFR3 mutations and a papillary architecture in UCB. FGFR3 mutations in lesions with a papillary architecture were first described by Billerey et al in tissue sections from low-grade papillary UCB, but more recent studies of tissue sections have demonstrated FGFR3 mutations in both low-grade and highgrade papillary NMIUC. 24, 25, [44] [45] [46] [47] A flat (nonpapillary)
architecture was associated with a significantly higher rate of mutations (P 5 .03) in SWI/SNF chromatin remodeling complex genes. In addition to the association with chromatin remodeling genes, other genes such as TP53, SDHC, BRIP1, and NF1 were also found to be significantly more associated with a flat architecture. These findings provide new insight into the molecular classification of UCB with new markers and further support the existence of at least 2 molecular signatures in urothelial carcinomas. 48, 49 One is associated with FGFR3 alterations and a papillary architecture, and the other is associated with a flat architecture, alterations in the TP53 pathway, and/or genetic alterations in the SWI/SNF chromatin remodeling complex. The correlation of the genomic findings with histological findings also found an association between genomic alterations and invasion. Genetic alterations in FOXL2 and PTPRS were identified only in patients with pT1 disease and were absent in all noninvasive UCB cases in this cohort; this suggests that they might represent markers of progression in UCB. Although these genetic alterations have been previously described in urinary carcinoma, their relation with stage has not been previously reported. 50 The correlation of the smoking history with the genomic results showed that alterations in 3 genes-MDM2, ATM, and SMARC4-were associated with the smoking status. MDM2 amplifications were significantly associated with a history of smoking (P 5 .04), whereas ATM and SMARC4A were significantly more associated with a nonsmoking history with P values of .01 and .03, respectively. These findings in MDM2 are in contrast to findings in lung carcinoma, for which MDM2 amplifications were not reported to correlate with a history of smoking in a meta-analysis reported by Bai et al. 51 Conversely, ATM mutations were significantly more common in nonsmoker patients; this finding is similar to findings of prior studies evaluating lung and breast carcinoma. 52, 53 Mutations in SMARC4A, another gene in the SWI/SNF chromatin remodeling complex, have been reported in 75% of small cell carcinomas of the ovary (hypercalcemic-type mutations) but in only 3.1% of carcinomas of the urinary tract (Catalogue of Somatic Mutations in Cancer). 50 Its relation with smoking has not been previously reported. An area for potential future investigation is the use of targeted therapy for cases of HR NMIUC because we identified several potentially actionable genetic alterations in ERBB2, CREBBP, and FGFR3 mutations among patients with refractory disease. These mutations were not found solely in patients with disease refractory to BCG, but they can potentially play a therapeutic role in the event of refractoriness to BCG treatment. For instance, ERBB2 mutations or amplifications were found in 24% of the patients with refractory disease in our series. It would be interesting to evaluate whether NMIUC refractory to BCG can potentially be treated with an expanding number of anti-human epidermal growth factor receptor 2 agents, such as trastuzumab, lapatinib, ado-trastuzumab emtansine, and pertuzumab, as suggested by Carneiro et al 54 and
Ross et al 55 for cases of advanced UCB. Similarly, tumors with activating mutations of FGFR3 might be sensitive to FGFR family inhibitors such as BGJ398. 56, 57 Another gene that might be subject to targeted therapy is CREBBP. CREBBP mutations can potentially be treated with mocetinostat, a potent selective inhibitor of histone acetyltransferases 1, 2, 3, and 11; it is currently in a phase 2 clinical trial for advanced bladder cancer. 58 In addition, the presence of genomic alterations in the DNA repair-associated genes ATM and RB1 might predict a response to cisplatin-based chemotherapy, as demonstrated in muscle-invasive bladder carcinomas by Plimack et al. 59 Despite the promising results of this study, limitations include its small size, which compromised our power to detect small effect estimates. Future studies with larger sample sizes are needed to more effectively assess the association of BCG treatment and alterations in ARID1A, EP300, and CDKN1A. In addition, not all samples were collected from treatment-naive patients because some patients had been treated with intravesical BCG before the collection of the analyzed specimens. At this moment, it is unknown what the impact of a prior BCG treatment would be on the genomic profile of the tumor cells.
Original Article
In summary, this study shows that urine specimens represent a viable, powerful platform for NGS analysis of HR NMIUC. The use of urine specimens would eliminate a major limitation in the analysis of HR NMIUC, which is the lack of sufficient tissue for high-coverage NGS analysis. Urine specimens can provide a genomic signature of HR NMIUC that can help with the molecular classification of UCB and can tailor the treatment of patients with HR NMIUC.
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